Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 3,000 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the insider directly owned 396,989 shares of the company’s stock, valued at $9,924,725. This trade represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.00, for a total transaction of $31,176.00.
• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.00, for a total transaction of $10,714.00.
• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Stock Down 0.6%

Shares of Adaptive Biotechnologies stock traded down $0.14 during trading hours on Wednesday, hitting $25.25. The company had a trading volume of 1,706,441 shares, compared to its average volume of 2,868,770. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The company’s 50-day moving average is $21.00 and its two-hundred day moving average is $17.02. The company has a market cap of $4.03 billion, a P/E ratio of -61.59 and a beta of 2.08. Adaptive Biotechnologies Corporation has a twelve month low of $11.92 and a twelve month high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The company had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share. Adaptive Biotechnologies’s revenue was up 21.5% compared to the same quarter last year. Analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ADPT has been the subject of several research reports. TD Cowen boosted their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Guggenheim boosted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Piper Sandler raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.42.

Institutional Trading of Adaptive Biotechnologies

Institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth $28,000. Allworth Financial LP acquired a new position in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $35,000. EverSource Wealth Advisors LLC raised its position in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV bought a new stake in Adaptive Biotechnologies in the first quarter valued at $45,000. Finally, Assetmark Inc. lifted its position in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.